In a phase I clinical trial, AS1411 delivered by continuous infusion at doses up to 40 mg/kg/day specifically inhibited nucleolin without causing serious side effects in a variety of tumor types (ClinicalTrials.gov identifier NCT00881244). Here, NUCLEOLIN is linked to neoplasm.